2026 H1 - tulosraportti
69 päivää sitten
‧45 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 84 | ||
| 196 | ||
| 695 | ||
| 152 | ||
| 1 328 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·2 t sitten · MuokattuByron Fitzgerald argues that the real bottleneck and value in the Pb-212 market does not lie in the isotope itself, but in the network that can deliver it on time. See the video at the link below. His main points: Pb-212 "does not wait". The half-life is only 10.6 hours, so after one day in transit most of it is gone. You therefore cannot produce it in one place and ship it worldwide, the dose must be made regionally and delivered within approx. one day. New IAEA rules make shipping much more difficult. The A2 value for Pb-212 in Type A packages has dropped sharply (approx. 222 times), so you can ship far fewer doses in one standard package. That increases costs and complexity. The solution is networks. Th-228 (half-life ~1.9 years) can be stored and planned, and used in generators to make Pb-212 near where it is to be used. Therefore, the two most important things become: Secure access to parent isotope (Th-228) Qualified regional compounding sites that can deliver within the time window Networks are built before approval. No Pb-212 medicine is approved yet, but the most advanced are moving toward Phase 3. Those who build or secure a functioning network of compounding sites now will sit on the scarce resource when the first medicines are approved. https://lnkd.in/p/epSGextm
·9 t sittenHow long do you guys think this wilderness wandering will last then?
·11 t sitten · MuokattuWhat on earth are they doing - one factory in Norway and then another factory in the US, AI and AY? And then you wonder if this is really what they are going to use the emi funds for - to build a factory in the US (because it is closer to the market and less travel time for the radioactivity?) And this before getting a sale worth recognizing as revenue (after a year or so)? Then they are biting off more than they can chew - a la Northvolt in Sweden - which was going to build factories here and there in Europe - because the market would become so huge (it got saturated by China)Have faith that those who have made the decision have better, broader and more information than you. And take it for granted that the decisions are made with the best of intentions. Everything else is just speculation
·21 t sittenWhere do you think this stock is in say 3-5 years. Have just started saving a bit in stocks. Have everything in Thor and will buy as I have money to spare. It is not large sums like some talk about in here, but still what I manage to set aside with 4 kids, a normally good job and income But thinking about whether it is better to put my money in a fund or something. Is just more exciting to follow Thor and what they manage to achieve going forward, but what is really the point if Max rise is small change against a fund..Folks this is not about a fortune. I am under 10000 and can bear to lose absolutely everything. But fun to buy this now when it is so low? Bought a bit when it was at 7 too. Then it was supposed to go to heaven.- ·1 päivä sittenI think this one will go up a bit now, awaiting news about the US venture. So when that arrives it could be fun 👍 dvs this is wishful thinking from me 🤣🙈Now that the Democrats have regained the majority in both chambers, we can expect the threat of major budget cuts against the research environment to disappear. It is highly likely that the new majority will roll back Trump's attempt to freeze research funds, thus once again ensuring strong public budgets for the cancer research that Thor Medical's American customers live on
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
69 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sitten · MuokattuByron Fitzgerald argues that the real bottleneck and value in the Pb-212 market does not lie in the isotope itself, but in the network that can deliver it on time. See the video at the link below. His main points: Pb-212 "does not wait". The half-life is only 10.6 hours, so after one day in transit most of it is gone. You therefore cannot produce it in one place and ship it worldwide, the dose must be made regionally and delivered within approx. one day. New IAEA rules make shipping much more difficult. The A2 value for Pb-212 in Type A packages has dropped sharply (approx. 222 times), so you can ship far fewer doses in one standard package. That increases costs and complexity. The solution is networks. Th-228 (half-life ~1.9 years) can be stored and planned, and used in generators to make Pb-212 near where it is to be used. Therefore, the two most important things become: Secure access to parent isotope (Th-228) Qualified regional compounding sites that can deliver within the time window Networks are built before approval. No Pb-212 medicine is approved yet, but the most advanced are moving toward Phase 3. Those who build or secure a functioning network of compounding sites now will sit on the scarce resource when the first medicines are approved. https://lnkd.in/p/epSGextm
- ·9 t sittenHow long do you guys think this wilderness wandering will last then?
- ·11 t sitten · MuokattuWhat on earth are they doing - one factory in Norway and then another factory in the US, AI and AY? And then you wonder if this is really what they are going to use the emi funds for - to build a factory in the US (because it is closer to the market and less travel time for the radioactivity?) And this before getting a sale worth recognizing as revenue (after a year or so)? Then they are biting off more than they can chew - a la Northvolt in Sweden - which was going to build factories here and there in Europe - because the market would become so huge (it got saturated by China)Have faith that those who have made the decision have better, broader and more information than you. And take it for granted that the decisions are made with the best of intentions. Everything else is just speculation
- ·21 t sittenWhere do you think this stock is in say 3-5 years. Have just started saving a bit in stocks. Have everything in Thor and will buy as I have money to spare. It is not large sums like some talk about in here, but still what I manage to set aside with 4 kids, a normally good job and income But thinking about whether it is better to put my money in a fund or something. Is just more exciting to follow Thor and what they manage to achieve going forward, but what is really the point if Max rise is small change against a fund..Folks this is not about a fortune. I am under 10000 and can bear to lose absolutely everything. But fun to buy this now when it is so low? Bought a bit when it was at 7 too. Then it was supposed to go to heaven.
- ·1 päivä sittenI think this one will go up a bit now, awaiting news about the US venture. So when that arrives it could be fun 👍 dvs this is wishful thinking from me 🤣🙈Now that the Democrats have regained the majority in both chambers, we can expect the threat of major budget cuts against the research environment to disappear. It is highly likely that the new majority will roll back Trump's attempt to freeze research funds, thus once again ensuring strong public budgets for the cancer research that Thor Medical's American customers live on
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 84 | ||
| 196 | ||
| 695 | ||
| 152 | ||
| 1 328 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 H1 - tulosraportti
69 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 - tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 - tulosraportti 28.8. | ||
2025 H2 - tulosraportti 26.2. | ||
2025 H1 - tulosraportti 29.8.2025 | ||
2024 H2 - tulosraportti 26.2.2025 | ||
2024 H1 - tulosraportti 30.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·2 t sitten · MuokattuByron Fitzgerald argues that the real bottleneck and value in the Pb-212 market does not lie in the isotope itself, but in the network that can deliver it on time. See the video at the link below. His main points: Pb-212 "does not wait". The half-life is only 10.6 hours, so after one day in transit most of it is gone. You therefore cannot produce it in one place and ship it worldwide, the dose must be made regionally and delivered within approx. one day. New IAEA rules make shipping much more difficult. The A2 value for Pb-212 in Type A packages has dropped sharply (approx. 222 times), so you can ship far fewer doses in one standard package. That increases costs and complexity. The solution is networks. Th-228 (half-life ~1.9 years) can be stored and planned, and used in generators to make Pb-212 near where it is to be used. Therefore, the two most important things become: Secure access to parent isotope (Th-228) Qualified regional compounding sites that can deliver within the time window Networks are built before approval. No Pb-212 medicine is approved yet, but the most advanced are moving toward Phase 3. Those who build or secure a functioning network of compounding sites now will sit on the scarce resource when the first medicines are approved. https://lnkd.in/p/epSGextm
- ·9 t sittenHow long do you guys think this wilderness wandering will last then?
- ·11 t sitten · MuokattuWhat on earth are they doing - one factory in Norway and then another factory in the US, AI and AY? And then you wonder if this is really what they are going to use the emi funds for - to build a factory in the US (because it is closer to the market and less travel time for the radioactivity?) And this before getting a sale worth recognizing as revenue (after a year or so)? Then they are biting off more than they can chew - a la Northvolt in Sweden - which was going to build factories here and there in Europe - because the market would become so huge (it got saturated by China)Have faith that those who have made the decision have better, broader and more information than you. And take it for granted that the decisions are made with the best of intentions. Everything else is just speculation
- ·21 t sittenWhere do you think this stock is in say 3-5 years. Have just started saving a bit in stocks. Have everything in Thor and will buy as I have money to spare. It is not large sums like some talk about in here, but still what I manage to set aside with 4 kids, a normally good job and income But thinking about whether it is better to put my money in a fund or something. Is just more exciting to follow Thor and what they manage to achieve going forward, but what is really the point if Max rise is small change against a fund..Folks this is not about a fortune. I am under 10000 and can bear to lose absolutely everything. But fun to buy this now when it is so low? Bought a bit when it was at 7 too. Then it was supposed to go to heaven.
- ·1 päivä sittenI think this one will go up a bit now, awaiting news about the US venture. So when that arrives it could be fun 👍 dvs this is wishful thinking from me 🤣🙈Now that the Democrats have regained the majority in both chambers, we can expect the threat of major budget cuts against the research environment to disappear. It is highly likely that the new majority will roll back Trump's attempt to freeze research funds, thus once again ensuring strong public budgets for the cancer research that Thor Medical's American customers live on
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 84 | ||
| 196 | ||
| 695 | ||
| 152 | ||
| 1 328 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt